RT Journal Article
T1 Efficacy of trovafloxacin in an in vitro pharmacodynamic simulation of an intraabdominal infection
A1 Alou Cervera, Luis
A1 Anta, María Lourdes
A1 Del Potro, Manuela G.
A1 Fuentes, Fernando
A1 Balcabao, Ignacio P.
A1 Gómez-Lus Centelles, María Luisa
A1 Prieto Prieto, José
AB An in vitro model simulating trovafloxacin concentrations in human serum after standard doses was used to investigate the activity of this drug with time against Bacteroides fragilis, Escherichia coli, Enterococcus faecalis and Staphylococcus aureus. Antibiotic concentrations used for each incubation period were: 4.24 mg/l (0-1 h), 3.69 mg/l (1-3 h), 3.25 mg/l (3-6 h), 2.38 mg/l (6-8 h), 1.35 mg/l (8-24 h). A 99.9% initial inoculum reduction (> 3 log10 cfu/ml) was defined as bactericidal activity. Bactericidal activity against these organisms was obtained with trovafloxacin after the first hour of incubation, and similar activity was obtained against B. fragilis, E. faecalis and S. aureus after 3 h, when they were tested individually. When the strains were tested as mixed culture, there was bactericidal activity against E. coli after 1 h incubation and after 3 h for S. aureus. This activity was observed against B. fragilis and E. faecalis after 6 h incubation in the mixed culture assays and after 3 h when organisms were tested individually. Regrowth was not observed over a 24 h period. These data show that trovafloxacin might be effective in intraabdominal infections caused by mixed aerobic and anaerobic microorganisms.
PB Elsevier
SN 0924-8579
YR 1999
FD 1999-07
LK https://hdl.handle.net/20.500.14352/107191
UL https://hdl.handle.net/20.500.14352/107191
LA eng
NO Alou L, Anta ML, Del Potro MG, Fuentes F, Balcabao IP, Gomez-Lus ML, Prieto J. Efficacy of trovafloxacin in an in vitro pharmacodynamic simulation of an intraabdominal infection. Int J Antimicrob Agents. 1999 Jul;12(2):135-9.
NO Pfizer Inc.
DS Docta Complutense
RD 11 abr 2025